|
CANCER OF THE BLOOD AND
BLOOD-FORMING SYSTEMS
The Leukemias
Reliable
statistics on death rates among chronic
leukemia patients are difficult to find.
Orthodoxy speaks in terms of a "median
survival" of only three years, and admits
that the effects of currently accepted
therapy have not been adequately evaluated?
The use of one
of the chemotherapy drugs of choice,
Leukeraz, carries with it the risk of
irreversible damage to the bone marrow.
Another chemotherapy drug, Cytoxan, has
produced cancer in rats and mice. Some of
the reactions Cytoxan has produced in humans
include: nausea, vomiting, bleeding and
inflammation of the colon, severe bleeding
from the bladder, and in males, possible
irreversible loss of sperm production. The
use of metabolic therapy does not involve
these kinds of risks. These facts should be
kept in mind while reading the following
case histories.
Laetrile Case
Histories
R106B: Chronic Lymphatic Leukemia
On July 3,
1973, this sixty-two-year-old man went to
his local doctor because he had developed a
lump on his neck. One week later, this was
biopsied, and because of the findings he was
referred to a blood and cancer specialist in
Sacramento, California. The consulting
physician’s summary dated August 6, 1973,
reads in part:
I feel
confident that he had chronic
lymphat-ic leukemia. As you know,
histologically the pathologists are
not able to determine on the basis
of a biopsy whether it is
lymphosarcoma or chronic lymphatic
leukemia. In recent years both of
these have been grouped together in
the so-called lymphoproliferative
disease group. I think the final
diagnosis depends upon the amount of
involvement of abnormal lymphoid
tissue.
In this
case, I note left axillary and left in-guinal
adenopathy and also the scar from the
biopsy of a node in the right
supraclavicular area.
It was my
feeling that he also had an en-larged
spleen.
We
obtained on July 27, 1973, a hemoglobin
of 15 gin., with a 47% hematocrit. The
white count was 24,000 [lab normals,
5,000-10,000), due to an 84% mature
lymphocytosis. The platelet count was
211,000 and the reticulocyte count was
1.4%. The direct Combs’’ was
negative. Serum
uric acid
6.3 mg.%; creatinine 1.1 mg.%.
I
obtained a liver-spleen scan, a copy
of which is enclosed. As you can
see, there was con-siderable
enlargement of the spleen noted.
I obtained
a bone marrow biopsy which in-dicated
approximately 60% infiltration of the
bone marrow by mature lymphocytes.
The
patient was started on Vincristine 2 mg.
I.V. weekly, Cytoxan three times a day
for one week with recommendation it be
cut down to 50 mg. two times a day, and
Prednisone 14 mg. morning and evening.
Mr. R. states
that a few days after hit lump was diagnosed
as chronic lymphatic leukemia a friend
approached him and his wife with information
about Laetrile. He stated he will be
"eternally grateful" for the information. On
July 23, 1973, he began metabolic therapy
including Laetrile.
In a letter to
the Richardson Clinic dated February 20,
1976, he summarized his reaction to the
diagnosis and the suggested treatments.
I took
chemotherapy for three days only. I
had started metabolic therapy on
July 23 and 24 [1973] and then
submitted [for the last time] to the
chemotherapy on July 27, 1973. Mixed
up? Yes. But, then what does one do
for cancer treatment when one knows
nothing to start with? It took only
a few minutes reading in the
Physician’s Desk Reference on
the third day I was on chemotherapy
to know what I wanted to do and what
I did not want to do. This is what
the book had to say about my drugs:
"Ovocen (Vincristine): Mode
of action is unknown but under
investigation.... Extreme care must
be used in calculating the dose. . .
Overdosing may have a serious or
fatal outcome." Cytoxin: "Its
mechanism of action is not known."
Nor did I want Prednisone,
about which I read more of the same.
I was not ready to die, not from
cancer and certainly not from the
poisons they were going to give me,
so I wouldn’t die from cancer.
The
patient states that prior to his
metabolic therapy treatment, although he
had worked hard every day, he did not
feel that he was in as vigorous good
health as he could be.
This
sixty-five-year-old gentleman and his wife
were interviewed at length in November,
1975, two years and four months following
the initiation of metabolic therapy. The
patient’s eyes sparkled like a young man’s,
and his skin was clear and fight. He had a
handsome gray beard that would have been a
pho-tographer’s delight. His mannerism was
animated.
He stated
that, before beginning metabolic therapy
including Laetrile, and adopting a
vegetarian diet, his mind was confused and
his disposition "not that good." He stated
he feels much better now and concluded:
There
is no sacrifice I would not
willingly make in the culinary field
in order to be in vigorous good
health. I cannot understand people
who say they cannot live this way.
All they are doing is confusing
self-indulgence with self-love. If
you love yourself you should not
find it that hard to use a bit of
self-discipline and give up your old
ways, including coffee, alcohol and
cigarettes so that you can get more
joy out of living. That is the
Lord’s way and His way is the way
I’m going to go.
He and his
wife of many years turned their gray
heads toward one another and smiled
tenderly. He took her hand in his and
looked up at me and said, "Thanks to Dr.
Richardson, I’m a whole man now."
Mr. R.
continues to lead an active life three
and one-half years following the
diagnosis of leukemia. With the
exception of three days of chemotherapy
he has had no treatment other than
metabolic therapy including Laetrile.
H1SSC: Leukemia
This
little girl was twelve years old at
the time of her initial diagnosis of
leukemia. She was on Methotroxate
and Cytoxin chemotherapy for
approximately one year.
The
parents of the patient were not
satisfied with their child’s progress
because she continued to grow weak. They
took her first to Dr. Contreras in
Mexico and later to the Richardson
Clinic where she began metabolic therapy
including Laetrile on January 22, 1975.
Her alkaline phosphatase was 134 mu/ml
at that time (laboratory normal 30-85 mu/ml).
White blood count was low (4,900 cu.mm)
due to previous chemo-therapy.
Miss C.
has continued on her maintenance
program of diet and vitamins. She has
returned to school and en-joys horseback
riding.
Blood stu4ies, dated April 12,
1976, returned to the Richardson
Clinic from the child’s home in
New Jersey showed the alkaline
phosphatase to be 12.00 Lu./1.
(lab normals, 10-50). The white
blood count was 5,000 (lab
normals, 4,800-10,800).
In a
letter dated July 20, 1976 (one and
one-half years after the patient
began metabolic therapy), the
following statement was made by the
patient’s phy-sician in New Jersey:
At [name omitted] last
examination 7/7/76, she was
in excellent health. There
are no palpable lymph nodes
or palpable organs. Her skin
was free of bruises.
The patient’s mother wrote the
Richardson Clinic In February,
1977, and said she continues to
be an apparently healthy, active
teenager with no trace of her
former disease.
K127J: Chronic
Lymphocytic Leukemia
This Fifty-three-year-old male
had a peripheral bone marrow
smear on May 9, 1975, at
St. John’s Hospital in Longview,
Washington. The diagnosis was
chronic lymphocytic leukemia.
Physician’s comment at the time
was as follows:
Leukemia at the present time
is regarded as in the early
stages and well
differentiated. If there are
no other clinical problems
and signs of the disease, it
might be appropriate to
observe the patient over a
period of time obtaining
CBC’s at three or six month
intervals.
The patient decided that, rather
than wait until his health began
to deteriorate, he would begin
meta-bolic therapy. He started
treatment May 29, 1975.
The patient noticed he had more
energy and was sleep-ing better
within a week.
In a
letter dated April 19, 1976, almost a
year Later, the patient stated he has
been careful about follow-lug the diet
and continuing the maintenance program
of Laetrile, other vitamins, and
enzymes. His gene-ral health has
remained good and he remains free of the
symptoms associated with Leukemia. His
white blood count has gradually gone
down from 15,000 to 12,000 (10,000 being
the high end of normal).
W130B: Chronic Myelogenous Leukemia
This
thirty-nine-year-old woman was found to have
a white blood count of 73,000 during a
routine physical examination in January,
1973. Subsequent bone marrow studies
referred to three different labora-tories
all confirmed the diagnosis of leukemia.
Further
studies at the Virginia Mason Clinic in
Seattle, Washington, reconfirmed the
diagnosis. She was placed on Myleran and
Zylorprim, after having had their possible
adverse side effects explained to her.
Mrs. W.
continued to follow the recommendations of
the Virginia Mason Clinic until July,
1975, at which time she came to the
Richardson Clinic for meta-bolic therapy
including Laetrile. Her white blood count
has continued to stay within normal limits
as of this writing, and the patient stated
she feels "so much bet-ter" than before
beginning metabolic therapy. It is, of
course, possible that this is a natural
remission and that at some future time her
white blood count might again climb.
However, the patient has already been spared
ten months of palliative treatment with Myle-ran,
an alkylating agent whose possible toxic
side ef-fects include: skin
hyperpigmentation (changes in skin color),
irreversible pulmonary fibrosis (formation
of scar tissue in the connective tissue
framework of the lungs leaving the patient
permanently unable to breathe properly), and
renal damage (kidney dam-age).
AIO2SM Chronic Lymphatic Leukemia
This
sixty-two-year-old male, Doctor of
Chiro-practic, first developed symptoms of
extreme weakness and night sweats in
October, 1972. Prior to that he had had a
gradual weight loss of twenty-five pounds.
In December,
1972, he went to his local M.D. Subsequent
laboratory exams showed an elevated WBC
(white blood count) of 350,000 and a
depressed RBC (red blood count) of 4.0 gins.
The diagnosis of chronic lymphatic leukemia
was made. Chest X-rays were negative for
mediastinal node and lung involve-ment. By
January 16, 1973, his WBC had risen to
710,000, seventy-one times normal.
His initial
contact with the Richardson Clinic was
February 1, 1973. The patient’s chief
complaint was extreme fatigue. He was
jaundiced and his liver and spleen were
enlarged. The patient began metabolic
therapy on his first visit.
During the
course of the next six months, his strength
increased and he was able to resume most of
his chiropractic duties. The jaundice
gradually de-creased and the liver and
spleen could no longer be felt. The liver
was still moderately tender in July, 1973,
however.
In addition to
the metabolic therapy regimen, the patient
was on Prednesone every other day as a con-trol
for his hemolytic (destruction of red blood
cells) tendency. The patient’s WBC continued
to be elevated, around 200,000 per cu. mm.,
but he manifested none of the other symptoms
usually associated with chronic lymphatic
leukemia, which are: enlarged liver and
spleen, extreme weakness, jaundice, and
hemorrhage.
In February,
1974, this patient decided to dis-continue
his Laetrile therapy. By May 14, 1974, his
WBC had risen to 815,000 per cu.mm.
(eighty-one times normal) and his hemoglobin
(RBC) had dropped to 5.0 gin. His
spleen and liver could be felt again. He
became jaundiced and was bothered by ankle
ede-ma.
He returned to
his metabolic therapy program, and his June
14, 1974, hematology (blood study) report
revealed WBC 595,000 per cu.mm. and
hemoglobin 8.9gm.
This patient
continues to have a WBC which is
considerably above normal (lab high normal,
10,000), averaging around 200,000. As of
this writing, how-ever, the patient—who,
three years ago, was too weak to work—is
able to carry on his daily routine as if he
did not have leukemia, provided he stays on
his diet and medication.
F121G: Chronic Lymphatic Leukemia, Coronary
Artery Disease, and Bronchitis
Mr. F. first
began to have difficulty with enlarged
axillary (under arm) lymph nodes in January,
1974. According to the patient, his local
doctor was not par-ticularly concerned
despite repeated complaints.
In October of
1974, Mr. F. sought another physician’s
opinion and was subsequently admitted to a
hospital in Livermore, California, for
diagnostic studies. These confirmed the
diagnoses of leukemia.
The patient
states the diagnosis made him quite
depressed because he had watched his
daughter die slowly from cancer. The
memories of her last days and the morphine
injections made him determined not to have
any radiation or chemotherapy.
About this
time, another daughter of his had been
reading about Laetrile and metabolic therapy
and sug-gested that her father try it.
The patient
began metabolic therapy in Novem-ber of
1974. The lymph nodes gradually decreased in
size. Mr. F. stated that he began to feel
better and no longer had pain shortly after
beginning treatment. He gained weight and
stated that, in his opinion, even the heart
pain was less of a problem.
Following the
initial course of therapy, he re-turned to
his local doctor for a routine check-up.
Upon the doctor’s advice, he was X-rayed
again, and the X-rays were negative for
regional lymphadenopathy (en-larged lymph
nodes) indicating the cancer was under
control.
The patient
stated he intends to remain on a main-tenance
dose of B17 because, in his opinion, it not
only has extended his life but has saved him
from the tortures-turn of orthodox
chemotherapy.
As of our last
contact with this patient, the symptoms of
his cancer had been absent for one and
one-half years. The only treatment he has
received is meta-bolic therapy including
Laetrile. |
